Obstructive sleep apnea (OSA) is an increasingly common chronic disorder in adults. Compared to the general population, OSA occurs more often in patients with coronary artery disease (CAD), with a reported prevalence of 38% to 65%. Emerging evidence indicates OSA initiates and exacerbates coronary atherosclerosis. Moreover, several observational studies indicate the presence of OSA was associated with higher rate of restenosis and repeat revascularization (mainly attributed non-culprit lesion revascularization) after percutaneous coronary intervention (PCI). OSA might initiate endothelial injury by repetitive bursts of sympathetic activity that occur with apneas and hypopneas. Moreover, untreated OSA reduces endothelial repair capacity. Whether OSA could exacerbate neointimal proliferation and plaque progression in the non-culprit lesion after drug-eluting stent (DES) implantation remains less studied. The investigators aimed to evaluate neointimal proliferation and strut coverage within stent segment as well as changes of plaque volume and morphology in the non-culprit lesion by optical coherence tomography (OCT) in patients with versus without OSA at 12-month follow-up.
Study Type
OBSERVATIONAL
Enrollment
84
Patients with OSA (apnea hypopnea index ≥15) based on sleep study
Patients without OSA (apnea hypopnea index \<15) based on sleep study
Beijing Anzhen Hospital, Capital Medical University
Beijing, China
RECRUITINGRelative proliferation volume within stent segment (% of stent volume)
Time frame: 12 months
Change of total lipid volume index in the non-culprit lesion
Time frame: 12 months
Maximum area stenosis within stent segment
Defined as minimal lumen area divided by the mean of reference lumen area
Time frame: 12 months
Total proliferation volume within stent segment
Time frame: 12 months
Maximum proliferation area within stent segment
Time frame: 12 months
Minimal lumen area within stent segment
Time frame: 12 months
Prevalence of uncovered struts, uncovered and apposed struts, malapposed struts
Time frame: 12 months
Prevalence of neoatherosclerosis
Time frame: 12 months
Total lipid volume index
Defined as the averaged lipid angle multiplied by lipid length; including culprit and non-culprit lesions
Time frame: Baseline
Prevalence of TCFA
In the culprit and non-culprit lesions
Time frame: Baseline
Prevalence of plaque rupture
In the culprit and non-culprit lesions
Time frame: Baseline
Rate of major adverse cardiac events (cardiac death, myocardial infarction, or ischemic-driven repeat revascularization)
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.